Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) recently announced the presentation of encouraging phase I data on its oncology candidate, ISIS-STAT3Rx, at the American Society of Clinical Oncology.

ISIS-STAT3Rx is being developed in collaboration with AstraZeneca (AZN - Analyst Report). Results from the open-label, dose-escalation study sahowed that treatment with ISIS-STAT3Rx helped achieve partial responses that were durable and prolonged in two out of three diffuse large B-cell lymphoma (DLBCL) patients who were refractory to earlier chemotherapy treatments.

The study was conducted in 15 patients with advanced solid tumors and lymphoma who had relapsed or were not responding to several chemotherapy regimens. Isis Pharma reported that a patient who had previously failed ten different chemotherapy regimens experienced a 50% reduction in tumor burden - partial response was maintained for more than a year and the patient continues to be treated with ISIS-STAT3Rx. Another patient with DLBCL experienced a 65% reduction in tumor burden and was, therefore, able to receive an autologous stem cell transplant. The patient remained disease free following the bone marrow transplant. 

ISIS-STAT3Rx is currently in two phase Ib/IIa studies from which results are expected next year – while one study is being conducted in patients with advanced lymphomas like DLBCL, the other study is being conducted in patients with metastatic liver cancer.

We note that ISIS-STAT3Rx is the first of Isis Pharma’s generation 2.5 chemistry candidates which are supposed to be significantly more potent than drugs currently in development and which could, therefore, be more effective in addressing difficult-to-treat cancers like DLBCL.

In addition to presenting the encouraging efficacy data on ISIS-STAT3Rx, Isis Pharma announced that it has achieved a milestone payment from AstraZeneca with the latter selecting a second development candidate under its collaboration agreement with Isis Pharma. The $10 million milestone payment was triggered with the selection of ISIS-ARRx, which will be evaluated as a monotherapy as well as in combination with other drugs for the treatment of prostate cancer.

Isis Pharma currently carries a Zacks Rank #2 (Buy). We are encouraged by the company’s progress with its pipeline - Isis Pharma has several candidates in phase II or phase III development. The next 12-18 months should be catalyst-filled with Isis Pharma expected to report results from several studies.

We view Kynamro’s Jan 2013 approval in the US as a major milestone for the company. Kynamro was launched in late Mar 2013 and we expect investor focus to remain on the product’s performance.

Other companies that currently look well-positioned include Biogen Idec (BIIB - Analyst Report) and Anika Therapeutics Inc. with both being Zacks Rank #1 (Strong Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%